Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dapagliflozin Effects on Mayor Adverse Cardiovascular Events in Patients With Acute Myocardial Infarction (DAPA-AMI). Randomized Clinical Trial

NCT04717986 is registered in ClinicalTrials.gov with Instituto Mexicano del Seguro Social as lead sponsor.

NCT NCT04717986
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04717986 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dapagliflozin Effects on Mayor Adverse Cardiovascular Events in Patients With Acute Myocardial Infarction (DAPA-AMI). Randomized Clinical Trial
Lead sponsor
Instituto Mexicano del Seguro Social
Phase
Not applicable
Overall status
Completed
Start date
January 26, 2021
Completion date
June 20, 2023
Enrollment
188 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myocardial infarction, angina, unstable, cardiovascular morbidity, heart failure